BioSpace News Archive

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that three abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming European Respiratory Society (“ERS”) International Congress 2022.

Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoReveal TM Dx Colon Cancer Assay.

At the ICMRBS 2022 Conference, Bruker today announces a new 8 mm 15 N TROSY Cryoprobe for enabling novel NMR functional structural biology investigations into larger globular proteins and protein complexes.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that BVF Partners L.P. and RA Capital Management have exercised their remaining tranche 1 warrants issued in connection with the Company’s November 2021 financing, resulting in proceeds of $20.9 million to the Company.

CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgAN, a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).

Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the publication of an article entitled “ Reduction in the Risk of Major Adverse Cardiovascular Events with the BET Protein Inhibitor Apabetalone in Patients with Recent Acute Coronary Syndrome, Type 2 Diabetes, and Moderate to High Likelihood of Non-Alcoholic Fatty Liver Disease ” in the American Journal of Preventive Cardiology.

Assure Holdings Corp. today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $6.2 million, before deducting underwriting discounts and other estimated expenses payable by the Company.

VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI | OTCQX: VHIBF) is pleased to announce a licensing agreement of subsidiary Intouch with Health’s (“Intouch”) digital, at-home pre-op solutions, Synopsis Home and Synopsis iQ, to the Bolton NHS Foundation Trust (the “Trust” or “Bolton”).

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).

Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced that data from IMPROVE-DiCE, Phase 2a, open-label trial, will be presented at the upcoming European Society of Cardiology (ESC) Congress, being held August 26-29, 2022 in Barcelona, Spain.